WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531999
CAS#: 152881-18-0
Description: KF 17837S is an adenosine A(2a) receptor antagonists, which is potential therapeutic and neuroprotective effects in Parkinson's disease.
Hodoodo Cat#: H531999
Name: KF 17837S
CAS#: 152881-18-0
Chemical Formula: C20H26N4O4
Exact Mass: 386.20
Molecular Weight: 386.452
Elemental Analysis: C, 62.16; H, 6.78; N, 14.50; O, 16.56
Synonym: KF 17837S; KF17837S; KF-17837S.
IUPAC/Chemical Name: 8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione
InChi Key: FSUNYKAEJIVAHY-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H26N4O4/c1-6-10-23-18-16(19(25)24(11-7-2)20(23)26)22(3)17(21-18)13-8-9-14(27-4)15(12-13)28-5/h8-9,12H,6-7,10-11H2,1-5H3
SMILES Code: O=C(N1CCC)N(CCC)C2=C(N(C)C(C3=CC=C(OC)C(OC)=C3)=N2)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 386.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Morelli M, Wardas J. Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res. 2001 Nov;3(6):545-56. PubMed PMID: 15111244.
2: Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, Salamone JD. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res. 2004 Jan 5;148(1-2):47-54. PubMed PMID: 14684247.
3: Bivalacqua TJ, Champion HC, Lambert DG, Kadowitz PJ. Vasodilator responses to adenosine and hyperemia are mediated by A(1) and A(2) receptors in the cat vascular bed. Am J Physiol Regul Integr Comp Physiol. 2002 Jun;282(6):R1696-709. PubMed PMID: 12010752.
